CTRI/2009/091/001039进行中（未招募）4 期
A phase IV, observer-blind, randomized, controlled, multicentric study to assess the safety and immunogenicity of GSK Biologicals HPV-16/18 L1 VLP AS04 vaccine (CervarixTM) administered intramuscularly according to a three-dose schedule (Day 0, Week 6, Month 6) in human immunodeficiency virus-infected (HIV+) female subjects aged 15 - 25 years, as compared to Mercks HPV-6/11/16/18 vaccine (Gardasil®).
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 708
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects who the investigator believes that they and/or their parent(s)/legally acceptable representative(s) (LAR) can and will comply with the requirements of the protocol.
- •A female between, and including, 15 and 25 years of age at the time of the first vaccination.
- •Written informed consent obtained from the subject and/or from the subject s parent or LAR.
- •Subjects willing to undergo HIV Voluntary Counseling and Testing (VCT) and willing to be informed of their HIV infection status.
- •For HIV seropositive subjects:
- •- Subjects must be HIV seropositive according to World Health Organization (WHO) case definition.
- •- Subject must be asymptomatic (or only have persistent generalized lymphadenopathy).
- •- Subjects should have a CD4 cell count > 350 cells/mm3.
- •- If currently taking antiretrovirals (ARVs), subjects must be on compliant to triple therapy (highly active ART) and have undetectable viral load on two previous clinical visits within the six months prior to study entry.
- •For HIV seronegative subjects:
- •- Subjects confirmed as HIV seronegative at the screening visit.
- •For non-virgin female subjects:
- •- Subjects must have no history of abnormal cytology or CIN 1/2/3.
- •- Subjects must have had no more than six life-time sexual partners prior to enrollment.
- •Subjects must have no history of congenital malformations of the uterine cervix, or history of cauterization or surgical procedures involving damage to the transformation zone of the cervix or stenosis.
- •Female subjects of non-childbearing potential may be enrolled in the study.
- •Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •- has practiced adequate contraception for 30 days prior to vaccination, and has a negative pregnancy test at screening and on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series.
排除标准
- •Previous vaccination against HPV, or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period (Day 0 to Month 24).
- •ART not compliant with the National Guidelines.
- •Active tuberculosis (TB) visit (criteria mandatory only for HIV+ subjects).
- •Current TB therapy.
- •Hemoglobin < 8.0 g/dL at the screening visit.
- •Creatinine > 1.5-fold the upper limit of normal (ULN) at the screening visit.
- •Alanine aminotransferase (ALT) > 2.5-fold ULN at the screening visit.
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period (Day 0 to Month 24).
- •Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs (with the exception of ART) within six months prior to the first vaccine dose.
- •Administration of a vaccine not foreseen by the study protocol within 30 days (Days 0 - 29) before the first dose of study vaccine/control.
- •Enrollment will be postponed until the subject is outside the specified window.
- •Planned administration of a vaccine not foreseen by the study protocol within 30 days before or 30 days after (i.e., Days 0 - 29) any dose of study vaccine.
- •Previous administration of components of the investigational vaccine.
- •Cancer or autoimmune disease under treatment.
- •Hypersensitivity to latex.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine/control.
- •Acute disease and/or fever at the time of enrollment.
- •Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory testing performed at the screening visit.
- •History of any neurological disorders or seizures.
- •Pregnant or breastfeeding female.
- •A subject planning to become pregnant, likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the study period, up to two months after the last vaccine dose (i.e., up to Month 8).
- •Concurrently participating in another clinical study, at any time during the study period (Day 0 to Month 24), in which the subject has been or will be exposed to an investigational or a non-investigational product.
- •Any medically diagnosed or suspected immunodeficient condition (other than HIV for HIV seropositive subjects), based on medical history, physical examination and/or laboratory tests results.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine/control or planned administration during the study period. Enrollment will be postponed until the subject is outside the specified window.
- •Administration of trimethoprim/sulphamethoxazole within seven days before the first dose of study vaccine/control, or planned administration of trimethoprim/sulphamethoxazole within seven days after the first dose of study vaccine/control.
- •Current drugs or alcohol abuse.
- •Child in care.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of safety and immunogenicity of a Human Papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) infected females.For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC US) and cervical intraepithelial neoplasia (CIN), CIN 1 and pre-cancerous lesions (CIN 2 and CIN 3), caused by oncogenic HPV types 16 and 18.MedDRA version: 19.0Level: LLTClassification code 10071147Term: Human papilloma virus immunizationSystem Organ Class: 100000004865MedDRA version: 19.0Level: LLTClassification code 10058580Term: Human papilloma virus serology testSystem Organ Class: 100000004848EUCTR2013-003429-28-EEGlaxoSmithKline Biologicals700
进行中（未招募）
1 期
Evaluation of the effectiveness of the antibiotic therapy in preventing complications after tooth extraction and evaluation of the effectiveness of the probiotic in preventing antibiotic adverse effectteeth needing extraction due to infectionsMedDRA version: 21.1Level: PTClassification code 10062132Term: Tooth extractionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: PTClassification code 10044034Term: Tooth disorderSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-001916-39-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA150
进行中（未招募）
1 期
A pharmacological study on efficacy and safety of OM-85 in children with recurrent respiratory tract infectionsEUCTR2016-002705-19-ITFONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO288
进行中（未招募）
1 期
A study to evaluate immunogenicity and safety of GlaxoSmithKline (GSK)'s Infanrix hexa vaccine (DTPa HBV IPV/Hib) versus MCM Vaccine BV's Vaxelis vaccine (DTaP5 HBV IPV Hib) in healthy infants and toddlersEUCTR2019-002988-10-ITGLAXOSMITHKLINE BIOLOGICALS500
进行中（未招募）
1 期
A study to evaluate immunogenicity and safety of GlaxoSmithKline (GSK)’s Infanrix hexa vaccine (DTPa HBV IPV/Hib) versus MCM Vaccine BV’s Vaxelis vaccine (DTaP5 HBV IPV Hib) in healthy infants and toddlersHealthy volunteers [Primary and booster immunization of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b (Hib)]MedDRA version: 21.1Level: LLTClassification code 10054187Term: Polio immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10069533Term: Haemophilus influenzae type b immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10069593Term: Pertussis immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10054181Term: Hepatitis B immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10054180Term: Diphtheria immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10054183Term: Tetanus immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2019-002988-10-DEGlaxoSmithKline Biologicals SA500